Search results
Results from the WOW.Com Content Network
Targeted alpha-particle therapy (or TAT) is an in-development method of targeted radionuclide therapy of various cancers. It employs radioactive substances which undergo alpha decay to treat diseased tissue at close proximity. [1] It has the potential to provide highly targeted treatment, especially to microscopic tumour cells.
A main target of PEA is proposed to be the peroxisome proliferator-activated receptor alpha (PPAR-α). [3] [4] PEA also has affinity to cannabinoid-like G-coupled receptors GPR55 and GPR119. [5] PEA cannot strictly be considered a classic endocannabinoid because it lacks affinity for the cannabinoid receptors CB1 and CB2. [6]
An alpha privative or, rarely, [1] privative a (from Latin alpha prīvātīvum, from Ancient Greek α στερητικόν) is the prefix a-or an-(before vowels) that is used in Indo-European languages such as Sanskrit and Greek and in words borrowed therefrom to express negation or absence, for example the English words of Greek origin atypical, anesthetic, and analgesic.
For this purpose, concentrations of up to 2% α-arbutin are found in face creams and serums and 0.5% in body creams. [ 1 ] α-Arbutin showed a significant reduction in melanin synthesis in cultured human melanoma cells and a three-dimensional human skin model, with melanin synthesis reduced to 40% of the control, indicating its potency as a ...
Very common adverse effects include nausea and headache (may affect more than 10% of people). Common adverse effects include injection site reactions, back pain, upper respiratory tract infections, melanocyte naevus, decreased appetite, migraine, dizziness, weakness, fatigue, lethargy, sleepiness, hot flashes, abdominal pain, diarrhea, vomiting, flushing, development of warts, spots, and ...
Eftilagimod alpha (INN; [1] development code IMP321 or efti) is a large-molecule cancer drug being developed by the clinical-stage biotechnology company Immutep. Efti is a soluble version of the immune checkpoint molecule LAG-3 .
HAMLET (Human Alpha-lactalbumin Made LEthal to Tumor cells) is a complex between alpha-lactalbumin and oleic acid that has been shown in cell culture experiments to induce cell death in tumor cells, but not in healthy cells. HAMLET is a possible chemotherapeutic agent with the ability to kill cancer cells. [1]
Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. [ 2 ] [ 5 ] Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate.